2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
No.85
“Periodontitis promotes hepatocellular carcinoma in Stelic Animal model (STAM) mice” (Sci. Rep., DOI: 10.1038/s41598-024-68422-7, 2024)
VIEW ARTICLE 
No.84
“StarD5 levels of expression correlate with onset and progression of steatosis and liver fibrosis” (Am J Physiol Gastrointest Liver Physiol., DOI: 10.1152/ajpgi.00024.2024, 2024)
VIEW ARTICLE
No.83
“A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models” (Nat Biotechnol., DOI: 10.1038/s41587-024-02143-0, 2024)
VIEW ARTICLE
No.82
“Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis” (Nat. Commun., DOI: 10.1038/s41467-023-42334-y, 2023)
VIEW ARTICLE
No.80
“Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in amurine model” (Front. Immunol., DOI:10.3389/fimmu.,2023)
VIEW ARTICLE
No.81
“Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan” (Sci Rep., DOI: 10.1038/s41598-023-44330-0, 2023)
VIEW ARTICLE
No.79
“Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH” (Int. J. Mol. Sci., DOI: 10.3390/ijms241612862.,2023)
VIEW ARTICLE
No.78
“Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH)” (Pharmacol Res Perspect., DOI: 10.1002/prp2.1094., 2023)
VIEW ARTICLE
No.77
“MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH” (Int J Mol Sci., DOI: 10.3390/ijms24098092., 2023)
VIEW ARTICLE
No.76
“MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity” (Cell Metab., DOI: 10.1016/j.cmet.2022.10.007., 2022)
VIEW ARTICLE
No.75
“Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH” (Cell Death & Disease., DOI: 10.1038/s41419-022-05452-x., 2022)
VIEW ARTICLE
No.74
“Hepatoprotective effects of Aureobasidium pullulans derived β 1,3-1,6 glucans in a murine model of non-alcoholic steatohepatitis - Journal of Clinical and Experimental Hepatology” (J Clin Exp Hepatol., DOI:https://doi.org/10.1016/j.jceh.2022.06.008., 2022)
VIEW ARTICLE
No.73
“Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia” (Cell Metab. DOI: 10.1016/j.cmet.2022.05.004., 2022)
VIEW ARTICLE
No.72
“A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE
No.71
“Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model”(PLoS One., DOI: 10.1371/journal.pone.0261310., 2022)
VIEW ARTICLE
No.70
“Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non Alcoholic Steatohepatitis” (Cells., DOI: 10.3390/cells11040720., 2022)
VIEW ARTICLE
No.69
“Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosisbut not NASH progression” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE
No.68
“Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function” (Mol Metab., doi: 10.1016/j.molmet.2022.101487., 2022)
VIEW ARTICLE
No.67
“Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments” (Transl Oncol., DOI: 10.1016/j.tranon.2021.101201., 2021)
VIEW ARTICLE
No.66
“In vivo diffuse reflectance spectroscopic analysis of fatty liver with I inflammation in mice” (Surg Open Sci., DOI: 10.1016/j.sopen.2021.07.002., 2021)
VIEW ARTICLE
No.65
“Inhalation: A means to explore and optimize nintedanib’s pharmacokinetic/pharmacodynamic relationship” (Pulm Pharmacol Ther.., DOI: 10.1016/j.pupt.2020.101933., 2021)
VIEW ARTICLE
No.64
“A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung” (Eur J Pharmacol.., DOI: 10.1016/j.ejphar.2020.173508., 2020)
VIEW ARTICLE
No.63
"Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice" (Cell Mol Gastroenterol Hepatol. DOI: 10.1016/j.jcmgh.2020.10.010., 2020)
VIEW ARTICLE
No.62
“Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition” (J Clin Exp Gastroenterol., DOI: 10.1194/jlr.RA120000924., 2020)
VIEW ARTICLE
No.61
“Changes in Function and Dynamics in Hepatic and Splenic Macrophages in Non-Alcoholic Fatty Liver Disease” (Clin Exp Gastroenterol., DOI: 10.2147/CEG.S248635., 2020)
VIEW ARTICLE
No.60
“Design and in vivo activity of A3 adenosine receptor agonist prodrugs” (Purinergic Signal., DOI: 10.1007/s11302-020-09715-0., 2020)
VIEW ARTICLE
No.59
“Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis” (Cell Rep Med ., DOI: DOI: 10.1016/j.xcrm.2020.100056., 2020)
VIEW ARTICLE
No.58
“Omaveloxolone and TX63682 Are Hepatoprotective in the STAM™ Mouse Model of Nonalcoholic Steatohepatitis” (J Biochem Mol Toxicol., DOI: 10.1002/jbt.22526., 2020)
VIEW ARTICLE
No.57
“6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Nonalcoholic Steatohepatitis” (J Med Chem., DOI: 10.1021/acs.jmedchem.0c00542., 2020)
VIEW ARTICLE
No.56
“Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice” (Sci Rep., DOI: 10.1038/s41598-020-64293-w)
VIEW ARTICLE
No.55
“[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis” (J Med Chem., DOI: 10.1021/acs.jmedchem.9b01440., 2020)
VIEW ARTICLE
No.54
“Intracellular toxic advanced glycation end-products (TAGE) in myoblasts may cause sarcopenia: Research article of a non-clinical study” (Diabetol. Metab. Syndr., DOI: 10.21203/rs.2.23269/v1, 2020)
VIEW ARTICLE
No.53
“Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH)” (Eur Radiol Exp., 4: 3., 2020)
VIEW ARTICLE
No.52
“Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.” (J Med Chem., DOI: 10.1021/acs.jmedchem.9b01621., 2020)
VIEW ARTICLE
No.51
“Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.” (Expert Opin Investig Drugs. 3:1-9., 2020)
VIEW ARTICLE
No.50
“A Blocking Monoclonal Antibody to CCL24 Alleviates Liver Fibrosis and Inflammation in Experimental Models for Liver Damage” (JHEP Reports, 10.1016/j.jhepr.2019.100064, 2020)
VIEW ARTICLE
No.49
“The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice.” (Int J Mol Med, 44(6):2256-2264, 2019)
VIEW ARTICLE
No.48
“Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis” (Sci Transl Med., 11(520), 2019)
VIEW ARTICLE
No.47
“Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis” (Cells, 8;8(11), 2019)
VIEW ARTICLE
No.46
“The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma”(Int. J. Mol. Sci. , 20(20), 5237, 2019)
VIEW ARTICLE
No.45
“Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.”(Toxicol Sci., 170(2):273-282, 2019)
VIEW ARTICLE
No.44
“A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease” (Biochemistry, 58(37):3911-3917, 2019)
VIEW ARTICLE
No.43
“Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents“ (Hepatol Commun., 3(8): 1085–1097, 2019)
VIEW ARTICLE
No.42
"Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis" (International Journal of Gastroenterology, DOI: 10.11648/j.ijg.20190301.12, 2019)
VIEW ARTICLE
No.41
"Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM™ mice" (Exp Anim., DOI: 10.1538/expanim.18-0152, 2019)
VIEW ARTICLE
No.40
"Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis" (Front Genet., May 29;10:486, 2019)
VIEW ARTICLE
No.39
"The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis" (J Cell Mol Med., 23:1759-1770, 2019)
VIEW ARTICLE
No.38
"Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan" (Sci Rep., Mar 8;9(1):4003, 2019)
VIEW ARTICLE
No.37
"Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology" (NPJ Precis Oncol., DOI: 10.1038/s41698-018-0068-8, 2018)
VIEW ARTICLE
No.36
"Dipeptidyl Peptidase 4 inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice" (CMGH, DOI: 10.1016/j.jcmgh.2018.08.008, 2018)
VIEW ARTICLE
No.35
“Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM™ mice” (Glycoconj J., Oct;35(5):467-476, 2018)
VIEW ARTICLE
No.34
“Integrative genomic analysis of mouse and human hepatocellular carcinoma” (Proc Natl Acad Sci U S A, DOI: 10.1073/pnas.1811029115, 2018)
VIEW ARTICLE
No.33
“Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model” (Liver Cancer, DOI: 10.1159/000491763, 2018)
VIEW ARTICLE
No.32
“Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH” (PLoS One, 13(5): e0194568 , 2018)
VIEW ARTICLE
No.31
“Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma” (World J Gastroenterol, 24(18):1989-1994, 2018)
VIEW ARTICLE
No.30
“Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma“ (FASEB J, DOI:10.1096/fj.201700866R, 2017)
VIEW ARTICLE
No.29
“MicroRNA deregulation in nonalcoholic steatohepatitisassociated liver carcinogenesis” (Oncotarget, 8:88517-88528, 2017)
VIEW ARTICLE
No.28
“Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet” (Oncotarget, 8:39978-39993, 2017)
VIEW ARTICLE
No.27
“Pathophysiological analysis of the progression of hepatic lesions in STAM™ mice.” (Physiological Research, 66:791-799, 2017)
VIEW ARTICLE
No.26
“Inhibition of the cell death pathway in non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation” (Molecular Cancer Research, DOI:10.1158/1541-7786.MCR-17-0109, 2017)
VIEW ARTICLE
No.25
“The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.” (Magn Reson Imaging, 38:123-128, 2017)
VIEW ARTICLE
No.24
“Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis” (J Pharmacol Exp Ther, 360:1-13, 2017)
VIEW ARTICLE
No.23
“Distinctly altered gut microbiota in the progression of liver disease” (Oncotarget, 7: 19355-19366, 2016)
VIEW ARTICLE
No.22
“Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes“ (Diabetology & Metabolic Syndrome, 8:45, 2016)
VIEW ARTICLE
No.21
“Solithromycin Diminishes Steatohepatitis by Modulating Gluconeogenesis and Inhibits Tumor Growth in a Diabetic Mouse Model of Non-Alcoholic Steatohepatitis” (J Immunol Infect Inflam Dis, 1:004, 2016)
VIEW ARTICLE
No.20
“Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis“ (PLoS One, 11:e0158156, 2016)
VIEW ARTICLE
No.19
“Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling” (Cell Press, 15:1175-1189, 2016)
VIEW ARTICLE
No.18
“Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease” (Int. J. Med. Sci, 13:169-178, 2016)
VIEW ARTICLE
No.17
“Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model” (Eur J Pharmacol, 772:22-32, 2016)
VIEW ARTICLE
No.16
“Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis” (Sci Rep., 12466, 2015)
VIEW ARTICLE
No.15
“Low cytochrome oxidase 4I1 links mitochondriazzzl dysfunction to obesity and type 2 diabetes in humans and mice” (Int J Obes, 39:1254-63, 2015)
VIEW ARTICLE
No.14
“Immunomodulatory spherical nucleic acids” (Proc Natl Acad Sci U S A, 31;112:3892-7, 2015)
VIEW ARTICLE
No.13
“Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis” (Oncol Rep, 33:1657-66, 2015)
VIEW ARTICLE
No.12
“In Vivo Efficacy Study of Milk Thistle Extract (ETHIS-094TM) in STAM™ Model of Nonalcoholic Steatohepatitis” (Drugs R D, 14:291-9, 2014)
VIEW ARTICLE
No.11
“Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging” (PLoS One, 9:e112667, 2014)
VIEW ARTICLE
No.10
“Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis” (Cancer Sci, 105:1254-60, 2014)
VIEW ARTICLE
No.9
“Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice” (Anticancer Res, 34:4849-4856, 2014)
VIEW ARTICLE
No.8
“L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.” (PLoS One, 9:e100627, 2014)
VIEW ARTICLE
No.7
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis” (Med Mol Morph, 47:137-149)
VIEW ARTICLE
No.6
“Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors” (PLoS One, 8:e83481, 2013)
VIEW ARTICLE
No.5
“Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide” (Int J Oncol, 42:831-838, 2013)
VIEW ARTICLE
No.4
“Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice” (Int J Exp Pathol, 94: 217-225, 2013)
VIEW ARTICLE
No.3
“A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma” (Med Mol Morph, 46:141-152, 2013)
VIEW ARTICLE
No.2
“Hydrogen-rich water prevents progression of non-alcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice” (Hepatology, 56:912-921, 2012)
VIEW ARTICLE
No.1
“Effects of Dietary Supplementation with Betaine on a Nonalcoholic Steatohepatitis (NASH) Mouse Model” (J Nutr Sci Vitaminol, 58:371–375, 2012)
VIEW ARTICLE